Study to measure biomarkers of collagen breakdown in COPD

• Conditions: J44.9; J45.9; Chronic obstructive pulmonary disease, unspecified; Asthma, unspecified

• Registration Number: DRKS00020343
• Lead Sponsor: Pneumolgisches Forschungsinstitut an der LungenClinic Grosshansdorf

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-12-30
• Study Completion: 2020-10-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 133

Inclusion Criteria

COPD:
- established diagnosis of COPD
- GOLD stage 1-3
- at least 10 py of smoking

Asthma:
- established diagnosis of asthma
- GINA 4 and 5 (at least medium-high dose of ICS/LABA combination)

Controls:
- no chronic lung disease
- no inhaled medication
- for (ex-)-smoking controls: at least 10 py of smoking

Exclusion Criteria

COPD:
- respiratory tract infection or exacerbation within the last 4 weeks
- FEV1 less than 30%
- autoimmune disease that could affect collagen breakdown

asthma:
- respiratory tract infection or exacerbation within the last 4 weeks
- FEV1 less than 30%
- autoimmune disease that could affect collagen breakdown

controls:
- respiratory tract infection within the last 4 weeks
- autoimmune disease that could affect collagen breakdown

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Measurement of biomarkers of collagen breakdown

Secondary Outcome Measures

Name	Time	Method
Association of biomarkers with indeces of disease severity (lung function, clinical phenotype)